Elicera Therapeutics CARMA Study: 8 of 12 Patients Achieve Complete Metabolic Response
Elicera Therapeutics has completed Phase I of its CARMA study, reporting that 8 out of 12 patients with B-cell lymphoma achieved a complete metabolic response. Eleven patients experienced tumor response.
Uppsala, Sweden – Elicera Therapeutics AB has concluded the Phase I part of its CARMA study, which assessed the safety and preliminary efficacy of its ELC-301 cell therapy.
The study involved patients diagnosed with B-cell lymphoma who had exhausted all curative treatment options. In total, eleven patients showed an objective tumor response, characterized by a reduction in tumor burden.
Of the twelve participants, eight achieved a complete metabolic response (CMR), indicating no active disease was detected during follow-up. This outcome suggests potential for the ELC-301 therapy in a patient group with limited therapeutic choices.
ELC-301 is a CAR T-cell therapy developed by Elicera Therapeutics, utilizing their iTANK technology. The company is proceeding with further evaluations to ascertain the therapy's full impact.